ContraFect Corporation (NASDAQ: CFRX) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitabiliy and institutional ownership.

Volatility & Risk

ContraFect Corporation has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Insider & Institutional Ownership

44.6% of ContraFect Corporation shares are owned by institutional investors. Comparatively, 27.9% of Aevi Genomic Medicine shares are owned by institutional investors. 9.3% of ContraFect Corporation shares are owned by company insiders. Comparatively, 24.8% of Aevi Genomic Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ContraFect Corporation and Aevi Genomic Medicine’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ContraFect Corporation N/A N/A -$32.36 million ($0.77) -1.75
Aevi Genomic Medicine N/A N/A -$41.42 million ($1.15) -1.08

ContraFect Corporation is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ContraFect Corporation and Aevi Genomic Medicine, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ContraFect Corporation 0 1 2 0 2.67
Aevi Genomic Medicine 0 1 1 0 2.50

ContraFect Corporation presently has a consensus price target of $5.00, suggesting a potential upside of 270.37%. Aevi Genomic Medicine has a consensus price target of $5.25, suggesting a potential upside of 323.39%. Given Aevi Genomic Medicine’s higher possible upside, analysts plainly believe Aevi Genomic Medicine is more favorable than ContraFect Corporation.

Profitability

This table compares ContraFect Corporation and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ContraFect Corporation N/A -202.93% -96.52%
Aevi Genomic Medicine N/A -108.08% -95.41%

Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with MarketBeat.com's FREE daily email newsletter.